Drug intelligence / Profile preview

DNN.22.17.036

Development stage: Phase 4
Lead developer: Ache Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

DNN.22.17.036 is an investigational drug being developed for the treatment of pattern hair loss (androgenetic alopecia) in male patients. It is administered topically, with 1 ml applied to the bald area of the scalp twice daily for 180 days. The drug is currently under clinical investigation and its precise mechanism of action has not been disclosed in public sources as of April 2025; it may have unknown side effects or risks, including skin irritation and headaches. The developer associated with this compound is Aché Laboratórios Farmacêuticos.

Beyond the preview

Go deeper on DNN.22.17.036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNN.22.17.036.

Explore the full profile